Treatment of nonmelanoma skin cancer with pro‐differentiation agents and photodynamic therapy: Preclinical and clinical studies (Review)
Photochemistry and Photobiology · 2024
DOI: 10.1111/php.13914 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Photochemistry and Photobiology, 2024. Verfasst von Sanjay Anand und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Photochemotherapy, Photosensitizing Agents, Skin Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Photodynamic therapy (PDT) is a nonscarring cancer treatment in which a pro‐drug (5‐ aminolevulinic acid , ALA) is applied, converted into a photosensitizer (protoporphyrin IX, PpIX) which is then activated by visible light. ALA‐PDT is now popular for treating nonmelanoma skin cancer (NMSC), but can be ineffective for larger skin tumors, mainly due to inadequate production of PpIX. Work over the past two decades has shown that differentiation‐promoting agents, including methotrexate (MTX), 5‐fluorouracil (5FU) and vitamin D (Vit D) can be combined with ALA‐PDT as neoadjuvants to promote tumor‐specific accumulation of PpIX, enhance tumor‐selective cell death, and improve therapeutic outcome. In this review, we provide a historical perspective of how the combinations of differentiation‐promoting agents with PDT (cPDT) evolved, including Initial discoveries, biochemical and molecular mechanisms, and clinical translation for the treatment of NMSCs. For added context, we also compare the differentiation‐promoting neoadjuvants with some other clinical PDT combinations such as surgery, laser ablation, iron‐chelating agents (CP94), and immunomodulators that do not induce differentiation. Although this review focuses mainly on the application of cPDT for NMSCs, the concepts and findings described here may be more broadly applicable towards improving the therapeutic outcomes of PDT treatment for other types of cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Dermatology and Plastic Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Sanjay Anand, Edward V Maytin
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Anand, S., Hasan, T., & Maytin, E. V. (2024). Treatment of nonmelanoma skin cancer with pro‐differentiation agents and photodynamic therapy: Preclinical and clinical studies (Review). Photochemistry and Photobiology. https://doi.org/10.1111/php.13914
Vancouver
Anand S, Hasan T, Maytin EV. Treatment of nonmelanoma skin cancer with pro‐differentiation agents and photodynamic therapy: Preclinical and clinical studies (Review). Photochemistry and Photobiology. 2024. doi:10.1111/php.13914
BibTeX
@article{Anand2024,
author = {Anand, Sanjay and Hasan, Tayyaba and Maytin, Edward V},
title = {Treatment of nonmelanoma skin cancer with pro‐differentiation agents and photodynamic therapy: Preclinical and clinical studies (Review)},
journal = {Photochemistry and Photobiology},
year = {2024},
doi = {10.1111/php.13914}
}
EUVIMED